Publicaciones en las que colabora con Rosario Palacios Muñoz (20)

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  2. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

2020

  1. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

  2. How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain

    HIV Medicine, Vol. 21, Núm. 2, pp. 128-134

  3. Risk of cardiovascular disease in patients with HIV infection undergoing antiretroviral therapy

    Revista Clinica Espanola, Vol. 220, Núm. 3, pp. 149-154

2019

  1. Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study

    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, Vol. 39, Núm. 5, pp. 497-505

  2. Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 6, pp. 373-379

2017

  1. Análisis de costes y de coste/eficacia de las pautas recomendadas por GESIDA/Plan Nacional sobre el Sida en 2016 para el tratamiento antirretroviral inicial en adultos infectados por el VIH

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 35, Núm. 2, pp. 88-99

2016

  1. Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics

    Open Forum Infectious Diseases, Vol. 3, Núm. 2

  2. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

  3. Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapy

    HIV Medicine, Vol. 17, Núm. 9, pp. 653-661

2015

  1. Consensus statement on metabolic disorders and cardiovascular risks in patients with human immunodeficiency virus

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 33, Núm. 1, pp. 40.e1-40.e16

  2. Executive summary of the consensus document on metabolic disorders and cardiovascular risk in patients with HIV infection

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 33, Núm. 1, pp. 41-47

2014

  1. Consensus document on the management of renal disease in HIV-infected patients

    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia

  2. Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 9, pp. 583-597

  3. Resumen ejecutivo del documento de consenso sobre el manejo de la patología renal en pacientes con infección por VIH

    Nefrologia, Vol. 34, Núm. 6, pp. 768-788

2007

  1. Cervical lipomatosis in HIV-infected patients: A case-control study

    HIV Medicine, Vol. 8, Núm. 1, pp. 17-21

  2. Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV infection: The ELADI study

    AIDS Research and Human Retroviruses, Vol. 23, Núm. 10, pp. 1237-1241

2006

  1. Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment- experienced patients with adverse events related to prior NRTI use: Data from a prospective, observational, multicenter study [3]

    Journal of Acquired Immune Deficiency Syndromes